Want to see HK:0690 full AI Analyst Report?
Uni-Bio Science Group Ltd. (0690) Ratios
Uni-Bio Science Group Ltd. Ratios
HK:0690's free cash flow for Q2 2026 was $11.41M. For the 2026 fiscal year, HK:0690's free cash flow was increased by $0.00 and operating cash flow was $11.41M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.23 | 2.58 | 2.07 | 2.22 | 2.18 |
| Quick Ratio | 2.87 | 2.31 | 1.76 | 1.84 | 1.75 |
| Cash Ratio | 1.74 | 0.53 | 1.13 | 1.09 | 0.91 |
| Solvency Ratio | 0.69 | 0.54 | 0.57 | 0.57 | 0.01 |
| Operating Cash Flow Ratio | 0.87 | 0.54 | 0.86 | 0.54 | 0.13 |
| Short-Term Operating Cash Flow Coverage | 2.36 | 1.54 | 6.83 | 4.35 | 2.61 |
| Net Current Asset Value | $ 167.78M | $ 126.87M | $ 85.28M | $ 102.62M | $ 108.38M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.17 | 0.22 | 0.14 | 0.08 | 0.02 |
| Debt-to-Equity Ratio | 0.24 | 0.35 | 0.22 | 0.12 | 0.03 |
| Debt-to-Capital Ratio | 0.19 | 0.26 | 0.18 | 0.10 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.12 | 0.15 | 0.11 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.40 | 1.59 | 1.59 | 1.50 | 1.54 |
| Debt Service Coverage Ratio | 2.78 | 2.36 | 5.81 | 4.88 | 0.34 |
| Interest Coverage Ratio | 59.73 | 75.58 | 86.55 | 101.20 | -14.22 |
| Debt to Market Cap | 0.14 | 0.27 | 0.10 | 0.02 | 0.01 |
| Interest Debt Per Share | 0.02 | 0.02 | 0.01 | 0.00 | 0.00 |
| Net Debt to EBITDA | -0.69 | 0.44 | -0.78 | -1.23 | -59.32 |
| Profitability Margins | |||||
| Gross Profit Margin | 83.17% | 83.38% | 81.04% | 76.06% | 78.38% |
| EBIT Margin | 16.59% | 16.70% | 15.82% | 9.92% | -5.53% |
| EBITDA Margin | 20.26% | 20.54% | 19.30% | 13.90% | 0.37% |
| Operating Profit Margin | 15.35% | 16.25% | 13.98% | 8.64% | -1.92% |
| Pretax Profit Margin | 17.32% | 16.49% | 15.66% | 9.83% | -5.66% |
| Net Profit Margin | 15.92% | 14.97% | 14.62% | 8.75% | -5.54% |
| Continuous Operations Profit Margin | 15.92% | 14.97% | 14.62% | 8.75% | -5.54% |
| Net Income Per EBT | 91.93% | 90.79% | 93.38% | 88.97% | 97.90% |
| EBT Per EBIT | 112.86% | 101.45% | 112.00% | 113.76% | 294.94% |
| Return on Assets (ROA) | 16.10% | 15.99% | 17.29% | 13.17% | -7.32% |
| Return on Equity (ROE) | 22.58% | 25.42% | 27.56% | 19.78% | -11.24% |
| Return on Capital Employed (ROCE) | 18.89% | 22.81% | 22.96% | 18.82% | -3.87% |
| Return on Invested Capital (ROIC) | 16.07% | 18.40% | 20.16% | 15.57% | -3.60% |
| Return on Tangible Assets | 17.23% | 17.21% | 19.12% | 14.75% | -7.80% |
| Earnings Yield | 13.59% | 22.47% | 15.47% | 8.41% | -3.66% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.99 | 7.87 | 6.69 | 6.45 | 4.51 |
| Payables Turnover | 4.66 | 6.03 | 9.87 | 20.03 | 14.52 |
| Inventory Turnover | 2.67 | 2.72 | 2.53 | 3.11 | 1.92 |
| Fixed Asset Turnover | 3.19 | 3.74 | 4.05 | 7.29 | 7.13 |
| Asset Turnover | 1.01 | 1.07 | 1.18 | 1.51 | 1.32 |
| Working Capital Turnover Ratio | 2.75 | 3.47 | 4.15 | 4.01 | 3.07 |
| Cash Conversion Cycle | 131.71 | 120.01 | 162.12 | 155.56 | 245.49 |
| Days of Sales Outstanding | 73.13 | 46.36 | 54.57 | 56.59 | 80.92 |
| Days of Inventory Outstanding | 136.89 | 134.13 | 144.54 | 117.19 | 189.72 |
| Days of Payables Outstanding | 78.31 | 60.49 | 36.99 | 18.23 | 25.14 |
| Operating Cycle | 210.02 | 180.50 | 199.11 | 173.79 | 270.64 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.02 | 0.01 | 0.02 | 0.01 | 0.00 |
| Free Cash Flow Per Share | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 |
| Dividend Paid and CapEx Coverage Ratio | 1.31 | 1.76 | 1.65 | 1.71 | 1.43 |
| Capital Expenditure Coverage Ratio | 1.73 | 1.76 | 1.65 | 1.71 | 1.43 |
| Operating Cash Flow Coverage Ratio | 0.92 | 0.58 | 1.76 | 2.15 | 2.15 |
| Operating Cash Flow to Sales Ratio | 0.15 | 0.12 | 0.20 | 0.11 | 0.03 |
| Free Cash Flow Yield | 5.55% | 7.79% | 8.53% | 4.42% | 0.67% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 7.37 | 4.45 | 6.47 | 11.89 | -27.32 |
| Price-to-Sales (P/S) Ratio | 1.17 | 0.67 | 0.95 | 1.04 | 1.51 |
| Price-to-Book (P/B) Ratio | 1.66 | 1.13 | 1.78 | 2.35 | 3.07 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 18.02 | 12.83 | 11.72 | 22.64 | 148.34 |
| Price-to-Operating Cash Flow Ratio | 7.60 | 5.52 | 4.64 | 9.41 | 44.45 |
| Price-to-Earnings Growth (PEG) Ratio | 0.47 | 0.21 | 0.08 | -0.04 | 0.38 |
| Enterprise Value Multiple | 5.09 | 3.69 | 4.12 | 6.25 | 347.69 |
| Enterprise Value | 604.55M | 418.58M | 385.33M | 382.42M | 457.21M |
| EV to EBITDA | 5.09 | 3.69 | 4.12 | 6.25 | 347.69 |
| EV to Sales | 1.03 | 0.76 | 0.79 | 0.87 | 1.29 |
| EV to Free Cash Flow | 15.86 | 14.58 | 9.85 | 18.90 | 126.72 |
| EV to Operating Cash Flow | 6.69 | 6.27 | 3.90 | 7.86 | 37.97 |
| Tangible Book Value Per Share | 0.06 | 0.05 | 0.03 | 0.03 | 0.02 |
| Shareholders’ Equity Per Share | 0.07 | 0.05 | 0.04 | 0.03 | 0.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.08 | 0.09 | 0.07 | 0.11 | 0.02 |
| Revenue Per Share | 0.10 | 0.09 | 0.08 | 0.07 | 0.06 |
| Net Income Per Share | 0.02 | 0.01 | 0.01 | 0.01 | -0.00 |
| Tax Burden | 0.92 | 0.91 | 0.93 | 0.89 | 0.98 |
| Interest Burden | 1.04 | 0.99 | 0.99 | 0.99 | 1.02 |
| Research & Development to Revenue | 0.08 | 0.10 | 0.08 | 0.08 | 0.14 |
| SG&A to Revenue | 0.60 | 0.56 | 0.10 | 0.11 | 0.13 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Income Quality | 0.97 | 0.81 | 1.39 | 1.12 | -0.60 |
Currency in HKD
